Research shows limited impact of ban on flavored e-cigarettes

Dec.01.2022
Research shows limited impact of ban on flavored e-cigarettes
The US ban on flavored e-cigarettes has had limited effectiveness, as users turn to alternative products and flavors.

On February 6, 2020, the United States Food and Drug Administration banned the sale of several flavors of electronic cigarettes, with some significant exceptions.


According to a survey published in the journal "Tobacco Control," out of 3500 adult users of electronic cigarettes who were surveyed, less than 5% of them stopped using electronic cigarettes due to the ban on flavored e-cigarettes. The remaining respondents switched to other types or flavors of electronic cigarettes or other tobacco products that were not covered by the ban.


More and more literature suggests that the flavorings in e-cigarettes can cause harm when inhaled, making a ban on these flavorings reasonable, according to tobacco research expert and Professor of Public Health Sciences and Community Center Deborah J. Ossip. "But bans don't seem to be effective. People, including young people, can still access flavored products and are still using them," she added. This statement was made at the University of Rochester Medical Center's Department of Public Health and Prevention.


According to Dongmei Li, the lead author of the study and associate professor of clinical and translational research, obstetrics and gynecology, and public health sciences, a significant part of the problem is that the ban does not cover newer products such as disposable e-cigarette pods and e-cigarette pods that use canisters instead of cartridges/boxes.


Other forms of flavored electronic cigarettes, particularly disposable ones, have become very popular after FDA policies were implemented," said Li. "The FDA's policies did not prohibit products with mint or tobacco flavors - our research indicates that many people switched to mint-flavored e-cigarettes after the ban. It seems that many people find menthol to be a favorable taste.


According to this study, nearly 30% of the survey respondents switched to canned or disposable flavored e-cigarettes, and another 30% switched to mint or tobacco flavored pods. Some reported turning to traditional tobacco products: 14% switched to combustible products like cigarettes, and 5% switched to smokeless products such as chewing or dipping tobacco. Less than 5% of respondents stopped using e-cigarettes after the FDA ban.


Researchers used statistical models to identify factors related to changes in e-cigarette usage behavior. They found a close correlation between using tank system e-cigarettes and switching to other flavors not regulated by the FDA's flavor law enforcement policies.


The use of mint-flavored electronic cigarettes over the past 30 days is associated with switching to mint-flavored electronic cigarettes. Those who reported smoking every day or every few days were more likely to switch to tobacco-flavored electronic cigarettes or combustible tobacco products.


On the other hand, people who use flavored electronic cigarettes without nicotine are more likely to quit smoking. Although the study was not intended to establish a causal relationship, the association supports previous research showing that reducing nicotine levels in cigarettes can help smokers quit. However, further research is needed to better understand the relationship between the use of low-nicotine electronic cigarettes and smoking cessation.


Looking towards the future, Li Dongmei believes that if this policy covers all flavors of electronic cigarettes (including mint and all types of electronic cigarettes) and actively monitors the implementation and compliance of the policy, then the policy may be effective. "Both are important in reducing the popularity of electronic cigarettes among young people in the United States," she said.


2FIRSTS will continue to cover this topic, with updates available on the "2FIRSTS APP". Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
Zhang Xiaotang Appointed Deputy Director of China’s Tobacco Regulator, Adding Another Finance-Background Official to Top Leadership
China’s State Council has appointed Zhang Xiaotang as deputy director of the State Tobacco Monopoly Administration, with the regulator’s official website now listing him as a Party leadership group member and deputy director. Zhang previously led Hebei China Tobacco and earlier headed the STMA’s finance and audit department. His appointment follows the elevation earlier this year of former tax official Yao Laiying to head the STMA, adding another senior official with a strong fiscal or financial-management background to China Tobacco’s top leadership in 2026.
News
Sep.20
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan files patent for cellulose-free nicotine pouch scaffold to replace microcrystalline cellulose
China Tobacco Yunnan Industrial Co., Ltd. has filed a patent application for a cellulose-free scaffold material for nicotine pouches, proposing a combination of bioceramic material, polydextrose and sugar alcohols to replace conventional microcrystalline cellulose and cellulose derivatives. The filing aims to address issues including powdery mouthfeel, residue and limited release control, while also reducing reliance on existing cellulose-based patent portfolios. In patent examples, one fast-release formulation reached a nicotine release rate of 50% at 10 minutes and more than 90% at 20 minutes.
Sep.02
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
PMI Pushes Smoke-Free Business in Latin America as Argentina Lifts Heated Tobacco Ban, Mexico City Share Tops 7%
Philip Morris International (PMI) showcased IQOS heated tobacco systems and nicotine pouch products at Technovation 2026 in Buenos Aires on October 7–8, presenting research on consumer attitudes, regulatory developments and illicit cigarette trade across Latin America. PMI Chief Global Growth Officer Stefano Volpetti said smoke-free products accounted for more than 7% of the Mexico City market. Argentina repealed its heated tobacco ban in May 2026 and introduced registration requirements for tobacco and nicotine products, while local media reported nicotine pouch sales in Mendoza. A PMI-commissioned survey found that only 8% of respondents across four Latin American countries were familiar with nicotine pouches. A separate KPMG study estimated illicit cigarette consumption at 77 billion sticks across 11 markets in Latin America and Canada in 2025.
PMI
Oct.13